Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Source
Original press release as distributed by PR Newswire, shown unedited.
Published

SAN MATEO, Calif., Nov. 4, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the third quarter ended September 30, 2026 and recent business progress.

Conference Call and Webcast Information

  • Date: Thursday, November 12, 2026 at 4:30 PM ET/1:30 PM PT
  • Participant Dial-in (North America): 1-800-836-8184
  • Participant Dial-in (International): 1-646-357-8785
  • Conference ID: 69368
  • Webcast Access: Click here 

The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.

A replay of the webcast will be available on the Talphera website for 90 days after the event.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Talphera Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-report-third-quarter-2026-financial-results-on-thursday-november-12-2026-302928338.html

This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.

Not part of the release

AlphAI analysis

ByAlphAI AI DeskAI-generated

Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.

Decision brief

The 30-second read

$TLPHNeutralLow
01

Why it matters

The earnings‑release notice provides a clear timeline for investors; no immediate price move is expected.

02

Market read

Standard earnings‑release announcement; limited short‑term trading impact.

03

What to watch

Potential FDA Breakthrough Device status for Niyad® may attract attention beyond the earnings call.

Relevance 4/10Novelty 4/10Timing: before Nov 12 earnings release

Background

Talphera is a specialty pharmaceutical firm developing Niyad®, a lyophilized nafamostat formulation with Breakthrough Device Designation from the FDA.

Company-level read

Ticker impact

$TLPHNeutralHigh confidence
Context

Talphera announced a conference call to release its Q3 2026 financial results on Nov 12, 2026.

Expected impact

likely modest pressure as traders await the results; no immediate catalyst.

Evidence & confidence

No new financial numbers are disclosed; the news is a standard earnings‑release notice.

Market effects

None significant; the announcement is company‑specific.

Limited to U.S. biotech/pharma investors tracking upcoming results.

Low

Counterpoint

If the market expects weak guidance, the call could trigger a sell‑off ahead of the release.

Key entities

  • Talphera, Inc.

    Specialty pharma focused on Niyad®.